EGFR and head and neck squamous cell carcinoma: Currently, for R/M HNSCC, the most used regimens include monotherapy or a combination of chemotherapeutics such as cisplatin (cDDP), carboplatin (CBDCA), 5-fluorouracil (5-FU), docetaxel, paclitaxel, immune-checkpoint inhibitors as pembrolizumab and nivolumab, and targeted treatment agents such as cetuximab (anti-epidermal growth factor receptor monoclonal antibody).